U.S. Sen. Cynthia Lummis said she will not seek reelection in 2026, confirming that her first term in the Senate will be her last. The Wyoming Republican made theU.S. Sen. Cynthia Lummis said she will not seek reelection in 2026, confirming that her first term in the Senate will be her last. The Wyoming Republican made the

Cynthia Lummis to Exit Senate After Current Term, Leaves Open Wyoming Seat in 2026

2025/12/20 21:34
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

U.S. Sen. Cynthia Lummis said she will not seek reelection in 2026, confirming that her first term in the Senate will be her last. The Wyoming Republican made the announcement publicly, signaling an open Senate race in a state that has long leaned Republican.

Lummis shared a brief message on X addressing voters directly. “Thank you, Wyoming! Serving our state has been the honor of my life,” she wrote. The post did not outline future plans, but it closed the door on another Senate campaign.

First elected in 2020, Lummis became Wyoming’s first woman in the U.S. Senate. She quickly gained national attention for her positions on fiscal policy and digital assets, turning a traditionally low profile seat into one closely watched by policy circles in Washington.

Decision shaped by Senate demands

Lummis said the decision followed reflection on the physical and time demands of serving in the Senate. She said another six year term would require a level of endurance she no longer wished to commit to, leading her to step aside rather than run again.

Despite the announcement, Lummis said she will serve out the remainder of her term through January 2027. She plans to remain active in legislative work and said she will support Republican efforts to retain the seat in the next election cycle.

Wyoming remains one of the most reliably Republican states in federal elections. As a result, political attention is expected to focus on the GOP primary rather than the general election. Potential successors have not yet formally entered the race.

Impact on crypto policy work

During her term, Lummis emerged as a leading Senate voice on cryptocurrency regulation. She consistently pushed for clearer rules for digital assets and argued that regulatory uncertainty was driving innovation outside the United States.

She co introduced the Responsible Financial Innovation Act alongside Sen. Kirsten Gillibrand, proposing a framework to define agency oversight of crypto markets. The bill became a foundation for later discussions, even as Congress struggled to reach consensus.

Lummis also backed proposals tied directly to Bitcoin, including legislation that explored the idea of a national Bitcoin reserve. While those efforts did not advance into law, they kept digital assets firmly on the Senate policy agenda.

Her departure removes one of crypto’s most visible supporters from the chamber. Lawmakers, industry groups, and regulators are now watching to see who will step into that role as Congress continues to debate digital asset legislation ahead of 2026.

Market Opportunity
OpenLedger Logo
OpenLedger Price(OPEN)
$0.14168
$0.14168$0.14168
-0.18%
USD
OpenLedger (OPEN) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09